Advancing new therapies for high–impact cardiopulmonary diseases
About Us
Herald Therapeutics is a clinical-stage biotechnology company developing targeted therapies for life-threatening pulmonary and cardiac diseases.
Our Pipeline
Our multi-indication platform focuses on delivering targeted, thyroid hormone-based therapies directly to the lungs to maximize efficacy and minimize off-target effects.
Our Lead Therapeutic
ThyrOxy™ is a lung-safe formulation of T3, engineered for targeted delivery to restore lung and heart function.
